Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Christopher Lee Wolfgang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8717-0373; OpenAlex author ID A5103031010. Sources: ClinicalTrials.gov.

Their work

Papers
195 (first author 11, last author 26)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
515
Papers, trials and grants by year

2011: 5 papers · 2012: 9 papers · 2013: 15 papers · 2014: 7 papers · 2015: 13 papers · 2016: 12 papers, 1 trial · 2017: 15 papers · 2018: 21 papers · 2019: 17 papers · 2020: 12 papers · 2021: 13 papers · 2022: 9 papers · 2023: 4 papers · 2024: 15 papers · 2025: 12 papers · 2026: 16 papers

Papers 50 of 195

  1. SPINK1-COL18A1 crosstalk shapes epigenome and drives cancer stemness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117806↗
  2. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  3. Clinical and molecular features of resected early onset pancreatic ductal adenocarcinoma: insights from the NCDB and cBioPortal. Co-author DOI 10.1016/j.hpb.2025.12.026↗
  4. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  5. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Co-author DOI 10.1016/j.hpb.2026.08.011↗
  6. Pancreatic ductal adenocarcinoma: Clinical trials to watch. Co-author DOI 10.1016/j.medj.2026.101268↗
  7. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  8. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  9. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  10. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  11. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  12. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  13. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  14. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  15. Proposal for an Objective and Concrete Definition for Determining Anatomic Resectability in Pancreatic Cancer: The Concept of the "Suitable Target". Last author DOI 10.1097/xcs.0000000000001738↗
  16. ASO Author Reflections: Arterial Reconstruction in Pancreatic Cancer: Shifting from Anatomical Feasibility Towards Biological Selection. Co-author DOI 10.1245/s10434-026-19469-5↗
  17. Histotripsy of Pancreatic Cancer Liver Metastases: Early Outcomes and Imaging Findings. Co-author DOI 10.1002/wjs.12646↗
  18. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  19. Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.surg.2024.109114↗
  20. Reversible chemoresistance of pancreatic cancer grown as spheroids. Co-author DOI 10.1080/1120009x.2024.2402177↗
  21. Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis. Co-author DOI 10.1093/jnci/djae294↗
  22. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1093/jnci/djaf196↗
  23. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  24. Transitional Type Circulating Tumor Cells Predict Systemic Recurrence and Support Risk Stratification for Chemotherapy After Resection of Pancreatic Ductal Ade… Last author DOI 10.1097/sla.0000000000006998↗
  25. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  26. Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17439-x↗
  27. The Impact of Social Determinants on Pancreatic Cancer Care in the United States. Co-author DOI 10.3390/cancers17121898↗
  28. The Impact of Social Determinants of Health on Supportive and Palliative Care in Pancreatic Cancer Management: A Narrative Review. Co-author DOI 10.3390/cancers17193254↗
  29. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  30. The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.06.004↗
  31. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  32. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  33. Factors associated with radiological misstaging of pancreatic ductal adenocarcinoma: A retrospective observational study. Co-author DOI 10.1067/j.cpradiol.2024.03.001↗
  34. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Last author DOI 10.1093/jnci/djae166↗
  35. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection. Co-author DOI 10.1097/sla.0000000000005977↗
  36. Progression of Site-specific Recurrence of Pancreatic Cancer and Implications for Treatment. Co-author DOI 10.1097/sla.0000000000006142↗
  37. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  38. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  39. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193↗
  40. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  41. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  42. Evaluation of AJCC Nodal Staging for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-16055-5↗
  43. Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer. Co-author DOI 10.3390/cancers16030489↗
  44. Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Ass… Last author DOI 10.1097/sla.0000000000005313↗
  45. Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy: An International Multicenter Study. Co-author DOI 10.1097/sla.0000000000005666↗
  46. Persistent Circulating Tumor Cells at 1 Year After Oncologic Resection Predict Late Recurrence in Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000005708↗
  47. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. Co-author DOI 10.1245/s10434-022-12901-6↗
  48. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-021-06410-y↗
  49. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
  50. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.sopen.2022.07.007↗

Trials 1

  1. Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma Principal investigator NCT02974764↗

Closest collaborators

The 25 strongest of 515 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ammar A. Javed · 56 shared papers, 2016–2026 · strength 8.60
  2. Jin Peng He · 73 shared papers, 2013–2026 · strength 7.21
  3. Joseph R. Habib · 31 shared papers, 2020–2026 · strength 5.81
  4. Matthew John Weiss · 53 shared papers, 2013–2024 · strength 4.30
  5. Izaak Quintus Molenaar · 26 shared papers, 2017–2026 · strength 4.23
  6. Marc G. Besselink · 25 shared papers, 2016–2026 · strength 4.18
  7. Ingmar Florin Rompen · 20 shared papers, 2024–2026 · strength 4.16
  8. Richard Andrew Burkhart · 35 shared papers, 2018–2026 · strength 3.87
  9. Ralph H. Hruban · 57 shared papers, 2011–2025 · strength 3.50
  10. Greg D. Sacks · 15 shared papers, 2024–2026 · strength 3.33
  11. Daniel Brock Hewitt · 14 shared papers, 2024–2026 · strength 3.01
  12. Lois A. Daamen · 13 shared papers, 2023–2026 · strength 2.64
  13. Hjalmar C. van Santvoort · 15 shared papers, 2017–2026 · strength 2.62
  14. Elliot K. Fishman · 31 shared papers, 2012–2024 · strength 2.46
  15. Vincent P. Groot · 22 shared papers, 2017–2026 · strength 2.43
  16. Joseph M. Herman · 52 shared papers, 2011–2022 · strength 2.41
  17. Kelly J. Lafaro · 16 shared papers, 2020–2026 · strength 2.30
  18. Jun Yu · 25 shared papers, 2013–2024 · strength 2.20
  19. Lei Zheng · 31 shared papers, 2012–2022 · strength 2.14
  20. Daniel A. Laheru · 39 shared papers, 2011–2022 · strength 2.13
  21. Bas Groot Koerkamp · 14 shared papers, 2017–2026 · strength 2.09
  22. William R. Burns · 16 shared papers, 2020–2025 · strength 2.01
  23. Thomas F. Stoop · 11 shared papers, 2024–2026 · strength 1.97
  24. Benedict Kinny‐Köster · 12 shared papers, 2020–2026 · strength 1.88
  25. Michael Goggins · 29 shared papers, 2011–2025 · strength 1.84

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.